Received Feb 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4G3X7 | IM |
vaccine was administered IM; This non-serious case was reported by a other health professional and described the occurrence of subcutaneous injection formulation administered by other route in a 39-year-old female patient who received MMR (Priorix) (batch number 4G3X7, expiry date 01-MAR-2027) for prophylaxis. On 12-FEB-2026, the patient received Priorix (intramuscular) .5 ml. On 12-FEB-2026, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: vaccine was administered IM). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-FEB-2026 The vaccine was administered intramuscularly, although the instructions indicated subcutaneous administration. They requested clarification on whether any side effects were expected and whether proper re-administration would be required to achieve full inoculation. There were no other products and no symptoms treated.